Mannatech Inc. (NASDAQ: MTEX), the leading innovator and provider of naturally sourced supplements based on Real Food Technology® solutions, announced the publication of a study that employed state-of-the-art technology to further explore the prebiotic effects of its Ambrotose® products. Performed by scientists at The Laboratory of Microbial Ecology and Technology (LabMET) at Ghent University (Universiteit Gent) in Ghent, Belgium, the study was published in the Antonie van Leeuwenhoek Journal of Microbiology.
"As The Economist magazine's recent cover story, "Microbes Maketh Man," made clear, the bacteria that populate the human body—particularly those in the gut—have an enormous impact on our health," commented Dr. Robert Sinnott, chief science officer and CEO at Mannatech Inc. "LabMET scientists have been leaders in the development of tools to better assess human gut bacterial populations. This is the first study to apply 16sRNA genes-based pyrosequencing in a Simulator of the Human Intestinal Microbial Ecosystem (SHIME) study."
The pyrosequencing technique allowed LabMET scientists to explore more deeply findings from a previous study published by Ghent University scientists, which showed that Advanced Ambrotose powder exhibited prebiotic effects along the entire colon.
Scientists at LabMET are devoted to investigating the optimal management of microbial resources, with the goal of developing novel products and processes that can improve the environment or human health in the most sustainable way.
To learn more about Mannatech and its Ambrotose technologies, visit mannatech.com. Learn more about Mannatech science and related publications and studies at mannatechscience.org.